CClinicalTrials.gg
Status unknownNCT04451486Updated Jun 30, 2020

A Phase I Study of SB Cell for the Enhanced Osseointegration of Guided Bone Regeneration in Implant Surgery

A Phase 1 interventional study of SB cells and SB cells in Guided Bone Regeneration, sponsored by Taipei Medical University. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-30.

Sponsored by Taipei Medical University · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Aug 2018, registered Jun 2020).
Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to enhance osseointegration of GBR in patients undergoing dental implant surgery.

Read the detailed description

This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to enhance osseointegration of GBR in patients undergoing dental implant surgery.

Enrolled subjects eligible to receive GBR procedure will be sequentially assigned to 1 of 3 treatment cohorts as follows:

Treatment dose 1 group:1×10*5 CD61-Lin- cells /0.25mL DPBS Treatment dose 2 group:1×10*6 CD61-Lin- cells /0.25mL DPBS Treatment dose 3 group:1×10*7 CD61-Lin- cells /0.25mL DPBS

After receiving the autologous SB cells solution mixed with 1 mL bone substitute, each first treated subject at each cohort will be followed up to 4-weeks. After the first subject at each cohort (3 subjects) complete a 4-weeks follow-up period, if investigator and sponsor judge that there is not either a safety concern or a dose-limiting toxicity (DLT) criteria is not met, 2 additional subjects within each cohort will be enrolled. A Data Safety Monitoring Committee will be conveyed after the first 3 treated subjects at each cohort complete undergo the dental implant procedure (12-weeks follow-up after GBR) to evaluate the safety and preliminary efficacy of SB cells administered during a GBR procedure, and will provide recommendations regarding study modification, continuation to enroll next subject(s), cohorts or study termination.

If the committee recommends further subject enrollment, sequential recruitment will continue until subjects for each treatment cohort are enrolled, treated and followed up to 24-weeks after GBR (12-weeks after dental implant) unless there is a safety concern judged by investigator, sponsor, or a dose-limiting toxicity (DLT) criteria is met. Once this situation occurs, the committee will assess the progress and safety data of all subjects enrolled, and will provide recommendations regarding study modification, continuation to enroll next subject in that or other cohorts, or will recommend study termination.

02

Conditions studied

  • Guided Bone Regeneration

Keywords

  • SB cell、autologous、Osseointegration
03

In context

Lead sponsor

Taipei Medical University is the lead sponsor of 245 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Subjects 20 years old and over;
  2. Sign of informed consent form;
  3. Patients with one missing tooth with D2, D3 bone density;
  4. Gums environment defined as alveolar bone height of 10 mm and above, bone width 8 mm and above;
  5. Have only one missing maxillary or mandibular posterior tooth (No. 4, 5, 6 or 7) who require a GBR prior to a dental implant.
  6. Bone defect(s) must be present with at least two walls missing.
  7. The opposing dentition must be nature teeth or fixed crowns or bridges on natural teeth or implants. Removable prostheses or dentures opposing the study implants are not allowed;
  8. Subject is able to understand and comply with protocol requirements, instructions and protocol stated restrictions

Exclusion criteria

Exclusion Criteria:

  1. Patients who have inadequate organ function described as below:

    1. ANC \< 1.5 x 109/L
    2. Platelets \< 100 x 109/L
    3. Hb \< 9 g/dL
    4. Serum bilirubin \< 1.5 x the upper limit of normal (ULN)
    5. Aspartate aminotransferase (AST [SGOT]) \< 2.5 × the ULN
    6. Alanine aminotransferase (ALT [SGPT]) > 2.5 × the ULN
    7. Serum creatinine > 1.5 mg/dL or a measured creatinine clearance \< 60 mL/min;
  2. History of neoplastic disease and had been treated with chemotherapy;
  3. Uncontrolled Diabetes Mellitus;
  4. Dialysis patients;
  5. Patients with cardiovascular disease;
  6. Osteoporosis patients and patients taking bisphosphonates;
  7. History of radiation therapy to the head and neck;
  8. Patients with temporomandibular disorder;
  9. Pregnant or nursing women;
  10. Presence of conditions requiring chronic routine prophylactic use of antibiotics (history of rheumatic heart disease, bacterial endocarditis, cardiac valvular anomalies, prosthetic joint replacements);
  11. Medical conditions requiring prolonged use of steroids;
  12. Physical handicaps that would interfere with the ability to perform adequate oral hygiene;
  13. Use of any investigational drug or device within the 30-day period immediately prior to implant surgery on study day 0;
  14. Alcoholism or drug abuse;
  15. Patients infected with HIV;
  16. Current smokers, ;
  17. Local inflammation, including untreated periodontitis;
  18. Mucosal diseases such as erosive lichen planus;
  19. History of local radiation therapy;
  20. Presence of osseous lesions;
  21. Unhealed extraction sites;
  22. Persistent intraoral infection;
  23. Patients with inadequate oral hygiene or unmotivated for adequate home care;
  24. Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability.
  25. Patient with a pathology present near the site of dental implantation.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Treatment dose 1

    1x10\*5 CD61-Lin- cells /0.25mL DPBS

    Drug: SB cells

  • Experimental
    Treatment dose 2

    1x10\*6 CD61-Lin- cells /0.25mL DPBS

    Drug: SB cells

  • Experimental
    Treatment dose 3

    1x10\*7 CD61-Lin- cells /0.25mL DPBS

    Drug: SB cells

Interventions

  • DrugSB cells

    1x10\*5 CD61-Lin- cells /0.25mL DPBS

  • DrugSB cells

    1x10\*6 CD61-Lin- cells /0.25mL DPBS

  • DrugSB cells

    1x10\*7 CD61-Lin- cells /0.25mL DPBS

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: Throughout the study, an average of 1 year

Secondary outcomes

  1. The maximum tolerated dose (MTD) of autologous-derived Small Blood Stem Cells in patients undergoing dental implant surgery.

    Time frame: Throughout the study, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
    Recruiting
08

References and documents

Publications

  • Schneider R. Prosthetic concerns about atrophic alveolar ridges. Postgrad Dent. 1999;6(2):3-7. PubMed 11360322 ↗
  • de Baat C, Kalk W, van 't Hof M. Factors connected with alveolar bone resorption among institutionalized elderly people. Community Dent Oral Epidemiol. 1993 Oct;21(5):317-20. doi: 10.1111/j.1600-0528.1993.tb00783.x. PubMed 8222609 ↗
  • Feng SW, Su YH, Lin YK, Wu YC, Huang YH, Yang FH, Chiang HJ, Yen Y, Wang PD. Small blood stem cells for enhancing early osseointegration formation on dental implants: a human phase I safety study. Stem Cell Res Ther. 2021 Jul 2;12(1):380. doi: 10.1186/s13287-021-02461-z. PubMed 34215319 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451486
Lead sponsor
Taipei Medical University
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Aug 10, 2018
Primary completion
Dec 12, 2019
Completion
Apr 25, 2021 (estimated)
Last update
Jun 30, 2020

Study contacts

Da-Yen Wang, PhD
Contact
dpw1@tmu.edu.tw
+886-2-2736-1661 ext. 5401
Sheng-Wei Feng, PhD
Contact
shengwei@tmu.edu.tw
+886-2-2736-1661 ext. 5401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion